Prognostication of diffuse large B-cell lymphoma in the rituximab era. - Wikidata - awgldk - TriplyDB

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

http://www.wikidata.org/entity/Q37833087

about

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients.The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients

P2860

Q37142412-3EAEA04D-B128-433B-B2B3-67ED1C1CA1C4 Q37934960-F9A22532-998B-470B-94CD-90120A17F6D4 Q37997054-C889D099-AC21-47EF-9735-2634DDAC0818 Q39989686-28BD2D51-7215-4B55-BB80-13D9FB0E61E9 Q40551018-1E01A178-B38E-469B-AD2C-7DDDA1562BFD Q53270181-91667E01-DB69-4550-A2D2-1ACAF9EBF7F0 Q58915114-1D235FA6-D494-442D-977A-6E7328BAF0AF

P2860

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

http://www.wikidata.org/entity/Q37833087

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

@en

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

@nl

type

label

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

@en

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

@nl

prefLabel

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

@en

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

@nl

P1433

Q37833087-FFE394DC-33B2-4C2F-83B6-0941BB064A8A

P1476

Q37833087-BEC68B1F-10F2-470A-A7C7-E9C756FACD6F

P2093

Q37833087-5A97E706-104B-4DF0-8557-A41F6CE3B3D9

Q37833087-61091530-3A63-47D3-811B-757D857BD1F1

Q37833087-629DF206-95D2-412E-8F90-D1EA586DC3F7

P2860

Q37833087-0354979B-AC89-4A65-B553-F2943F57FB77

Q37833087-05F24DBE-B152-4657-88F4-8705D1E26ACB

Q37833087-08B2A821-8063-4ACF-8E49-4B559D8D24B9

Q37833087-09297AFA-0D4F-42B1-8A3F-BC8CEF239E51

Q37833087-0A3AC3E8-D349-4517-9D5F-59CBEEA98C3B

Q37833087-0AA6068A-7CB7-46FE-8446-7F3D0460538D

Q37833087-0AB3A1C9-BE67-4466-AAEC-59C66277A72C

Q37833087-0AF5B83A-B738-432B-B489-0A0286822456

Q37833087-0F91A82E-B6FA-4DF6-A41D-4A4FCFDDF1C2

Q37833087-15B9AE06-6EF8-4BA1-8AF9-1574B2A182C3

P304

Q37833087-95C179ED-F616-4339-BB1E-6E7F84A17E05

P31

Q37833087-E50C722B-77B1-40FC-846B-8564BB8AB719

P356

Q37833087-8F6CBAD3-D024-44C4-B06C-326C01374492

P433

Q37833087-7E2F39D6-B869-49EA-A379-6826735CE1DB

P478

Q37833087-C8E666E5-A206-4844-AA37-E3580C13FEBF

P577

Q37833087-D1E4653E-F08F-4805-B1AF-7DE47F1F640D

P698

Q37833087-8C0B6031-6AF3-497A-9934-5A1C7FB87690

P356

10428194.2010.543716

P1433

Leukemia & Lymphoma

P1476

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

@en

P2093

Mary J Ninan

http://www.w3.org/2001/XMLSchema#string

Pankaj Gupta

http://www.w3.org/2001/XMLSchema#string

Punit D Wadhwa

http://www.w3.org/2001/XMLSchema#string

P2860

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Role of the F-box protein Skp2 in lymphomagenesis

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

p53, the cellular gatekeeper for growth and division

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

P304

360-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2010.543716

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21275631

http://www.w3.org/2001/XMLSchema#string